Reviva Pharmaceuticals Advances Schizophrenia Drug Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Source: Newsfilter
- Clinical Trial Progress: Reviva Pharmaceuticals plans to initiate its second Phase 3 trial (RECOVER-2) in mid-2026 to generate additional efficacy and safety data, thereby supporting the NDA submission for brilaroxazine in treating schizophrenia, demonstrating the company's commitment to addressing unmet medical needs.
- Safety and Tolerability: Existing data packages indicate that brilaroxazine has shown a well-tolerated long-term safety profile in over 900 subjects, with less than 1% of patients reporting symptom relapse during one year of treatment, highlighting the drug's potential in schizophrenia management.
- Financial Performance: For the fiscal year 2025, Reviva reported a net loss of approximately $19.9 million, or $5.48 per share, which is an improvement compared to a net loss of $29.9 million in 2024, reflecting the company's efforts in cost control and operational optimization.
- Funding Initiatives: Reviva completed a public equity offering in March 2026, raising $10 million, with plans to use the net proceeds to support the RECOVER-2 trial and other R&D activities, ensuring sufficient operational funding for the upcoming year.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
